Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus PIPRACIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus PIPRACIL.
DYCILL vs PIPRACIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), interfering with peptidoglycan cross-linking during cell wall assembly.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
3.375 g IV every 6 hours (piperacillin 3 g + tazobactam 0.375 g) over 30 minutes; for nosocomial pneumonia: 4.5 g IV every 6 hours over 30 minutes.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
0.7-1.2 hours in adults with normal renal function; prolonged to 3-6 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-4 hours.
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Primarily renal (tubular secretion and glomerular filtration) as unchanged drug (50-70%); biliary/fecal excretion is a minor route (approximately 10-20% as unchanged drug and metabolites).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic